Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study)
Elena Didenko Pedersen,1,2 Egon Stenager,3,4 JL Vadgaard,5 MB Jensen,6 R Schmid,7 N Meland,8 G Magnussen,9 Jette L Frederiksen10,11 1Akershus University Hospital, Department of Neurology, Loerenskog, Norway; 2Sandvika Nevrosenter, Sandvika, Norway; 3MS Clinic of Southern Jutland, Department of Neur...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-04-01
|
| Series: | Patient Preference and Adherence |
| Subjects: | |
| Online Access: | https://www.dovepress.com/adherence-to-subcutaneous-interferon-beta-1a-treatment-using-an-electr-peer-reviewed-article-PPA |
| _version_ | 1831645141649063936 |
|---|---|
| author | Pedersen ED Stenager E Vadgaard JL Jensen MB Schmid R Meland N Magnussen G Frederiksen JL |
| author_facet | Pedersen ED Stenager E Vadgaard JL Jensen MB Schmid R Meland N Magnussen G Frederiksen JL |
| author_sort | Pedersen ED |
| collection | DOAJ |
| description | Elena Didenko Pedersen,1,2 Egon Stenager,3,4 JL Vadgaard,5 MB Jensen,6 R Schmid,7 N Meland,8 G Magnussen,9 Jette L Frederiksen10,11 1Akershus University Hospital, Department of Neurology, Loerenskog, Norway; 2Sandvika Nevrosenter, Sandvika, Norway; 3MS Clinic of Southern Jutland, Department of Neurology, Hospital of Southern Denmark, Odense, Denmark; 4Institute of Regional Research, University of Southern Denmark, Odense, Denmark; 5Department of Neurology, Sjællands University Hospital, Roskilde NeuroCenter, Roskilde, Denmark; 6Department of Neurology, Nordsjaellands Hospital, Hilleroed, Denmark; 7MS Clinic, Department of Neurology, Vejle Hospital, Vejle, Denmark; 8Smerud Medical Research, Oslo, Norway; 9Merck Norway, An Affiliate of Merck AB (Merck AB NUF), Oslo, Norway; 10Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Science, Glostrup, Denmark; 11Institute of Clinical Medicine, Copenhagen University, Copenhagen, Denmark Background: Disease modifying drugs help control the course of relapsing remitting multiple sclerosis (RRMS); however, good adherence is needed for long-term outcomes.Objective: To evaluate patient adherence to treatment with subcutaneous interferon beta-1a using RebiSmart® and assess injection-site reactions and treatment satisfaction.Methods: This prospective, single-arm, open-label, noninterventional multicenter Phase IV trial included disease modifying drug-experienced mobile patients with RRMS. Adherence was measured over 12 weeks. Items 13–23, 35, 37, and 38 of the Multiple Sclerosis Treatment Concerns Questionnaire (injection-site reactions and treatment satisfaction) were recorded at 12 weeks.Results: Sixty patients were recruited (mean age 43.7 [±SD 7.9] years; 83% female; mean years since multiple sclerosis diagnosis 6.7 [SD 4.5]). Adherence data were obtained in 54 patients only due to technical problems with six devices. Over 12 weeks, 89% (n=48) of patients had ≥90% adherence to treatment. Most patients experienced mild influenza-like symptoms and injection-site reactions, and global side effects were minimal. Most patients (78%) rated the convenience as the most important aspect of the device, and most experienced no or mild pain.Conclusion: RRMS patients treated with subcutaneous interferon beta-1a, administered with RebiSmart, demonstrated generally good adherence, and the treatment was generally well tolerated. Keywords: adherence, multiple sclerosis, relapsing remitting MS, subcutaneous interferon beta-1a, RebiSmart, trial |
| first_indexed | 2024-12-19T13:30:29Z |
| format | Article |
| id | doaj.art-ba6de3766026433ca6b9d37f0feaa6b6 |
| institution | Directory Open Access Journal |
| issn | 1177-889X |
| language | English |
| last_indexed | 2024-12-19T13:30:29Z |
| publishDate | 2018-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Patient Preference and Adherence |
| spelling | doaj.art-ba6de3766026433ca6b9d37f0feaa6b62022-12-21T20:19:23ZengDove Medical PressPatient Preference and Adherence1177-889X2018-04-01Volume 1256957537872Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study)Pedersen EDStenager EVadgaard JLJensen MBSchmid RMeland NMagnussen GFrederiksen JLElena Didenko Pedersen,1,2 Egon Stenager,3,4 JL Vadgaard,5 MB Jensen,6 R Schmid,7 N Meland,8 G Magnussen,9 Jette L Frederiksen10,11 1Akershus University Hospital, Department of Neurology, Loerenskog, Norway; 2Sandvika Nevrosenter, Sandvika, Norway; 3MS Clinic of Southern Jutland, Department of Neurology, Hospital of Southern Denmark, Odense, Denmark; 4Institute of Regional Research, University of Southern Denmark, Odense, Denmark; 5Department of Neurology, Sjællands University Hospital, Roskilde NeuroCenter, Roskilde, Denmark; 6Department of Neurology, Nordsjaellands Hospital, Hilleroed, Denmark; 7MS Clinic, Department of Neurology, Vejle Hospital, Vejle, Denmark; 8Smerud Medical Research, Oslo, Norway; 9Merck Norway, An Affiliate of Merck AB (Merck AB NUF), Oslo, Norway; 10Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Science, Glostrup, Denmark; 11Institute of Clinical Medicine, Copenhagen University, Copenhagen, Denmark Background: Disease modifying drugs help control the course of relapsing remitting multiple sclerosis (RRMS); however, good adherence is needed for long-term outcomes.Objective: To evaluate patient adherence to treatment with subcutaneous interferon beta-1a using RebiSmart® and assess injection-site reactions and treatment satisfaction.Methods: This prospective, single-arm, open-label, noninterventional multicenter Phase IV trial included disease modifying drug-experienced mobile patients with RRMS. Adherence was measured over 12 weeks. Items 13–23, 35, 37, and 38 of the Multiple Sclerosis Treatment Concerns Questionnaire (injection-site reactions and treatment satisfaction) were recorded at 12 weeks.Results: Sixty patients were recruited (mean age 43.7 [±SD 7.9] years; 83% female; mean years since multiple sclerosis diagnosis 6.7 [SD 4.5]). Adherence data were obtained in 54 patients only due to technical problems with six devices. Over 12 weeks, 89% (n=48) of patients had ≥90% adherence to treatment. Most patients experienced mild influenza-like symptoms and injection-site reactions, and global side effects were minimal. Most patients (78%) rated the convenience as the most important aspect of the device, and most experienced no or mild pain.Conclusion: RRMS patients treated with subcutaneous interferon beta-1a, administered with RebiSmart, demonstrated generally good adherence, and the treatment was generally well tolerated. Keywords: adherence, multiple sclerosis, relapsing remitting MS, subcutaneous interferon beta-1a, RebiSmart, trialhttps://www.dovepress.com/adherence-to-subcutaneous-interferon-beta-1a-treatment-using-an-electr-peer-reviewed-article-PPAAdherencemultiple sclerosisrelapsing remitting MSsubcutaneous interferon beta-1aRebiSmart®trial |
| spellingShingle | Pedersen ED Stenager E Vadgaard JL Jensen MB Schmid R Meland N Magnussen G Frederiksen JL Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study) Patient Preference and Adherence Adherence multiple sclerosis relapsing remitting MS subcutaneous interferon beta-1a RebiSmart® trial |
| title | Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study) |
| title_full | Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study) |
| title_fullStr | Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study) |
| title_full_unstemmed | Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study) |
| title_short | Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study) |
| title_sort | adherence to subcutaneous interferon beta 1a treatment using an electronic injection device a prospective open label scandinavian noninterventional study the scansmart study |
| topic | Adherence multiple sclerosis relapsing remitting MS subcutaneous interferon beta-1a RebiSmart® trial |
| url | https://www.dovepress.com/adherence-to-subcutaneous-interferon-beta-1a-treatment-using-an-electr-peer-reviewed-article-PPA |
| work_keys_str_mv | AT pedersened adherencetosubcutaneousinterferonbeta1atreatmentusinganelectronicinjectiondeviceaprospectiveopenlabelscandinaviannoninterventionalstudythescansmartstudy AT stenagere adherencetosubcutaneousinterferonbeta1atreatmentusinganelectronicinjectiondeviceaprospectiveopenlabelscandinaviannoninterventionalstudythescansmartstudy AT vadgaardjl adherencetosubcutaneousinterferonbeta1atreatmentusinganelectronicinjectiondeviceaprospectiveopenlabelscandinaviannoninterventionalstudythescansmartstudy AT jensenmb adherencetosubcutaneousinterferonbeta1atreatmentusinganelectronicinjectiondeviceaprospectiveopenlabelscandinaviannoninterventionalstudythescansmartstudy AT schmidr adherencetosubcutaneousinterferonbeta1atreatmentusinganelectronicinjectiondeviceaprospectiveopenlabelscandinaviannoninterventionalstudythescansmartstudy AT melandn adherencetosubcutaneousinterferonbeta1atreatmentusinganelectronicinjectiondeviceaprospectiveopenlabelscandinaviannoninterventionalstudythescansmartstudy AT magnusseng adherencetosubcutaneousinterferonbeta1atreatmentusinganelectronicinjectiondeviceaprospectiveopenlabelscandinaviannoninterventionalstudythescansmartstudy AT frederiksenjl adherencetosubcutaneousinterferonbeta1atreatmentusinganelectronicinjectiondeviceaprospectiveopenlabelscandinaviannoninterventionalstudythescansmartstudy |